GO
Loading...

Enter multiple symbols separated by commas

Amgen Inc

More

  • Big Week For Biotech Monday, 10 Mar 2008 | 6:46 PM ET

    This is a big week for the world's top-two biotechnology companies and their investors. What’s going on and how can you trade it?

  • One Giant Leap for MannKind Monday, 10 Mar 2008 | 5:11 PM ET

    Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.

  • Amgen And Genentech: A Big Biotech Double Play Monday, 10 Mar 2008 | 10:50 AM ET
    AMGEN

    This is a big week for the world's top-two biotechnology companies and their investors. Amgen goes before an FDA Advisory Committee Thursday about the side effects of its bread-and-butter franchise Aranesp.

  • Next Weeks Trades: Wal-Mart, Costco & More Friday, 7 Mar 2008 | 7:28 PM ET
    web_extra_weekahead_thumb.jpg

    In Friday’s Web Extra find out how the traders recommend playing Wal-Mart, Costco, Pfizer, Amgen and Genentech in the week ahead.

  • Tech's 'Horses' Hold Nasdaq Hostage in Bear Market Friday, 7 Mar 2008 | 1:46 PM ET
    bull and bear outside frankfurt stock exchange

    Nasdaq's bear market is likely to persist longer than the pullback in the broader stock market unless the recently battered technology heavyweights make solid comebacks.

  • Analyst: Pfizer Should Buy Amgen or Wyeth Friday, 7 Mar 2008 | 10:48 AM ET

    I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • Drug Money Still A "Healthy Flow" To Democrats Monday, 3 Mar 2008 | 9:29 AM ET
    democrat_drug_money.jpg

    On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...

  • Lightning Round: Medco, Amgen, Yum! and More Thursday, 28 Feb 2008 | 8:12 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Fund Manager: Buy Fast -- and Buy These Names Tuesday, 26 Feb 2008 | 3:29 PM ET
    picks_pans_badge.jpg

    The time to buy stocks, says Michael Cuggino, is now. The president and portfolio manager of Permanent Portfolio Funds offered CNBC very specific reasons to buy -- and the specific stocks you need.

  • Coffee Talk With Amgen And Roche Wednesday, 20 Feb 2008 | 3:15 PM ET
    richman_linda.jpg

    Perhaps this item belongs in the "Funny Business" blog of my witty colleague Jane Wells, but when I saw this headline cross the Dow Jones Newswire this afternoon under the "Market Talk" blurb they move several times during the trading day, I just had to throw it up on my blog. I didn't know DJ had hired "Linda Richman" to write copy, or maybe Mike Myers needs a little extra income.

  • Genentech, JNJ, Pfizer: Big Days Ahead For Pharma Friday, 15 Feb 2008 | 9:41 AM ET
    february_partial_calendar.jpg

    Taking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.

  • Stock Picks Your Portfolio Might Love Thursday, 14 Feb 2008 | 6:02 PM ET
    picks_pans_badge.jpg

    Stocks are down this Valentine's Day, and there's nothing to love about that.  To keep investors from getting their hearts broken by their portfolios, CNBC enlisted the help of market experts.

  • Buying Biotechs? Watch the Headlines Thursday, 14 Feb 2008 | 12:41 PM ET
    picks_pans_badge.jpg

    How should an investor play biotech stocks?  Pay attention to individual events involving individual companies, according to Bear Stearns biotech analyst Mark Schoenebaum.

  • World's Biggest Biotech Wednesday, 13 Feb 2008 | 6:45 PM ET
    graphic_sector_trade.jpg

    Amgen, the biggest biotech by revenue, is trying to regain investors' confidence after a 32% drop in the last year. How should you trade?

  • obama_clinton.jpg

    In their stump speeches and debates, Hillary Clinton and Barack Obama often talk about pushing back against the Washington influence of the powerful pharmaceutical lobby and keeping drug company profits in check.

  • Glaxo, Merck, SGP & Amgen: Readers Have a Lot to Say Friday, 1 Feb 2008 | 10:51 AM ET

    It's a new month. Time to clean out the inbox. Regarding my post earlier this week about Sen. Chuck Grassley's office breaking the "Nature" embargo on the leak of the GlaxoSmithKline Avandia study, I heard from the "Nature" article reporter.

  • amgen_sign.jpg

    In the wake of my semantic disagreement with Amgen over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number.

  • Comeback Continues; Microsoft to Rally Market Friday Thursday, 24 Jan 2008 | 6:24 PM ET
    graphic_word_ofthe_street.jpg

    A slew of strong earnings, good jobs data and a bounce in commodities kept stocks afloat for the second day in a row. And with Microsoft blowing away its numbers after the bell, the traders expect the rally to continue.

  • AMGEN

    I just got back to my desk after doing a breaking news alert on Amgen's earnings. To sum up, I characterized the report as a mixed bag. The anemia drug sales weren't as bad as expected. Overall revenue was higher than consensus. And fourth quarter earnings per share was three cents higher than the Street.

  • Amgen Profit Up on Anermia Drug Sales Thursday, 24 Jan 2008 | 4:45 PM ET

    Amgen reported on Thursday that its fourth-quarter profit edged higher, on a reversal of declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.